Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Janssen, Pharmacyclics In Anti-Cancer Development Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Janssen, Pharmacyclics In Anti-Cancer Development Pact

50/50 profit-loss agreement covers development/commercialization activities

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

J&J unit Janssen Biotech has entered an agreement with Pharmacyclics, Inc. to jointly develop and market the anti-cancer compound, PCI-32765. Several Phase I and II studies are ongoing across a panel of B-cell malignancy disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma.

The companies have entered into a worldwide 50/50 profit-loss agreement, sharing development and commercialization activities. Janssen has made an upfront payment of $150 million and will make additional payments based on certain development and regulatory milestones.

“The agreement with Pharmacyclics is an opportunity to bring a new form of oral therapy to patients with B-cell malignancies,” said William N. Hait, M.D., Ph.D., global therapeutic head of Oncology for Janssen. ”PCI-32765 is an innovative compound, with broad applicability and the potential to help a large number of patients with B-cell malignancies.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters